Autek China Inc.: history, ownership, mission, how it works & makes money

Meet Autek China Inc., the Hefei-born eye health specialist founded in 2000 that, trading as 300595.SZ on the Shenzhen exchange, has grown into a vertically integrated maker of orthokeratology and myopia-control solutions-launching the Dream David lens in 2014, expanding beyond rigid lenses by 2020, and operating over 490 optical service terminals by 2021; with a market capitalization of about CN¥13.78 billion (July 1, 2025), 895.29 million shares outstanding and insiders holding roughly 49.69%, Autek pairs R&D-driven product lines and AI partnerships with direct sales to hospitals, clinics and retailers, reporting revenue of CN¥1.81 billion in 2024 and strong profitability metrics (profit margin 29.53%, operating margin 40.55% as of March 31, 2025), while pursuing regional expansion, a 39% stake acquisition in Fuzhou Autek Medical Devices in 2023, and analyst-forecasted growth that targets a multi-year CAGR of 12% and projected regional sales increases as it tackles China's rising myopia challenge.

Autek China Inc. (300595.SZ): Intro

• 2000 - Company founded in Hefei, Anhui Province.
• 2014 - Launched flagship Dream David orthokeratology lens (orthokeratology/non‑surgical overnight myopia control).
• 2020 - Expanded product portfolio beyond rigid lenses into broader myopia control products and services.
• 2021 - Established over 490 optical service terminals to strengthen direct consumer engagement and aftercare.
• 2023 - Acquired a 39% equity stake in Fuzhou Autek Medical Devices Co., Ltd., deepening presence in medical device manufacturing and clinical channels.
• Late 2025 - Continues product innovation and market expansion across eye‑health and myopia management segments.

• Founders and management holdings (founder‑led R&D emphasis).
• Institutional investors and mutual funds active on the Shenzhen board.
• Public retail shareholders through on‑exchange free float.
• Strategic holdings: 39% stake in Fuzhou Autek Medical Devices Co., Ltd. (2023).

• Key corporate link: Mission Statement, Vision, & Core Values (2026) of Autek China Inc.

• Scale orthokeratology and myopia management adoption in China and selective overseas markets.
• Integrate clinical channels, optical service terminals and medical device manufacturing to capture diagnosis‑to‑treatment value chain.
• Invest in product R&D (fit design, materials, myopia‑control efficacy) and service quality/aftercare.

• R&D & manufacturing: Design and produce rigid orthokeratology lenses (e.g., Dream David) and related myopia‑control products.
• Clinical fitting & follow‑up: Optical service terminals provide eye exams, lens fitting, follow‑up visits and refits-critical for orthokeratology outcomes and recurring revenue.
• Medical devices: Through Fuzhou Autek Medical Devices, supply clinically oriented devices and consumables to hospitals and clinics.
• Distribution: Direct retail via franchise/owned terminals, partnerships with optometrists, and B2B supply to hospitals/clinics.

• Sales of rigid orthokeratology lenses and myopia‑control products (one‑off product sales plus replacement lenses).
• Clinical service fees and recurring follow‑up/aftercare visits at optical service terminals.
• Medical device sales and OEM/ODM contracts via Fuzhou Autek Medical Devices.
• Training, certification and channel support services for franchise/partner optometrists.

Autek China Inc. (300595.SZ): History

• Early 2000s: Founding and initial product development in automotive electronics.
• 2010s: Expanded R&D into sensor fusion and advanced driver-assistance components.
• Listed on Shenzhen Stock Exchange under ticker 300595; scaled production and quality systems.
• 2020s: Increased focus on software-hardware integration, exports, and strategic OEM contracts.

• Autek China Inc. is publicly traded on the Shenzhen Stock Exchange (300595.SZ).
• Insiders (management, founders, affiliated entities) collectively control a significant stake (~49.69%), aligning long-term operational incentives with shareholder value.
• Institutional investors own about 6.99%, indicating moderate institutional participation and potential for increased coverage/liquidity over time.
• The remaining ~43.32% is held by public shareholders, providing a diversified retail and non-affiliated base.

• Mission: Develop and supply intelligent electronic components and integrated systems that enable safer, more efficient vehicles and industrial platforms. See corporate direction and values here: Mission Statement, Vision, & Core Values (2026) of Autek China Inc.
• How it works: R&D-led product development (hardware + embedded software), qualification with OEMs, volume manufacturing, and after-sales support. Key functional areas include sensor development, ECU design, software integration, and production scaling.
• How it makes money: Primary revenue streams are product sales of automotive electronics and systems to OEMs and Tier-1 suppliers, long-term supply contracts, aftermarket parts, and incremental services (software updates, diagnostics, customization).

Autek China Inc. (300595.SZ): Ownership Structure

• Mission and Values: Autek China Inc. is committed to providing innovative eye health and myopia prevention and control technologies and services in China. The company emphasizes integrity with transparent governance, innovation in product and process development, and a strong customer commitment. A dedicated customer service team maintains an average response time of less than 24 hours for inquiries. Sustainability and teamwork further shape operations, with mentorship programs, team-building workshops, and initiatives to reduce carbon footprint and landfill waste.

• Corporate ownership snapshot (representative structure): major shareholders, institutional holdings, and public float influence strategic priorities-R&D intensity, commercial partnerships, and sustainability investments-while management retains strong voting influence to preserve long-term product roadmaps.

• How ownership shapes mission execution:
  • Integrity & governance: institutional and management stakes enforce disclosure and compliance norms.
  • Innovation funding: approximately 6-10% of annual revenue is allocated to R&D to sustain product pipeline and technology upgrades.
  • Customer commitment: operational KPIs (customer response <24 hours) are monitored and resourced by both management and board-level sponsors.
  • Sustainability targets: ownership-backed initiatives aim to reduce carbon intensity and lower waste-to-landfill rates year-over-year (target reductions >20% within three years from baseline).

• Financial & operational metrics (indicative):

  Metric	Latest Report / Target
  Annual revenue (most recent fiscal year)	RMB 600-1,200 million (range indicative of growth stage medical device/services firms)
  R&D spend	~6-10% of revenue
  Employees	~1,000-1,500
  Customer service avg response	<24 hours
  Sustainability target	Min. 20-30% reduction in carbon/waste intensity within 3-5 years

Autek China Inc. (300595.SZ): Mission and Values

• Ophthalmology Services: Clinic-level optometry, screening, orthokeratology fitting, post-fit follow-up, and optical retail through a proprietary network of service terminals.
• Products: Design, manufacture and distribution of ophthalmic medical devices and optometry consumables, including orthokeratology (ortho-k) specialty lenses and related fitting systems.

• Research & Development: In-house R&D teams develop lens geometries, materials and manufacturing tooling; company reports ongoing multi-year projects to optimize myopia-control geometries and comfort.
• Manufacturing: Precision lens fabrication lines and automated finishing processes ensure repeatability across batches; production management integrates optical metrology at multiple points.
• Service Network: A nationwide optical service terminal network provides direct consumer fitting, education and follow-up-reducing dependence on third-party distribution.
• Technology Partnerships: Strategic alliances with AI and imaging firms to incorporate AI-driven diagnostics, digital fitting workflows and production optimization.

• Device Sales: One-time and repeat sales of ophthalmic devices and ortho-k lenses to clinics and directly to consumers via service terminals.
• Service Revenue: Fitting fees, follow-up visits, orthokeratology programs (subscription-like models for lens replacement and monitoring), and optical retail margins.
• Channel and OEM: B2B distribution and OEM manufacturing for partner brands and clinical groups.
• Software & Diagnostics: Licensing and SaaS-style revenues from AI-driven fitting and diagnostic platforms integrated into clinic workflows.

• Customer Lifetime Value (CLTV): Repeat lens replacement cycles (typically every 6-12 months for orthokeratology) and ongoing follow-up create higher CLTV than single-sale devices.
• Gross Margins: Product manufacturing benefits from scale and automation; services deliver higher margin through direct-to-consumer captive channels and value-added clinical care.
• R&D Payoff: Investment in novel lens geometries and digital fitting reduces fitting time and returns improved retention; R&D intensity is a strategic priority to sustain differentiation.
• AI & Efficiency Gains: AI-driven diagnostics reduce appointment time, improve first-fit success rates and lower aftercare costs-improving throughput per clinic terminal.

• Automated corneal topography analysis to accelerate lens selection and increase first-fit success.
• Production process AI to reduce rejects and improve throughput.
• Tele-optometry modules enabling remote follow-up and monitoring for pediatric myopia-control programs.

Autek China Inc. (300595.SZ): How It Works

• Primary revenue streams:
  • Direct sales of orthokeratology (OK) lenses to hospitals, eye clinics and specialty optical retailers.
  • Sales of general contact lenses and related care products (solutions, cases, maintenance items).
  • Ophthalmic optometry technology services, including operation and management of optical service terminals (in-clinic equipment, refraction and fitting services).
  • After-sales and service contracts, training, and technology-enabled optometry support.
• Distribution and customers:
  • Hospitals and ophthalmology departments (prescription-driven, high-value clinical channel).
  • Private eye clinics and franchise optical retailers (product and fitting services).
  • Institutional partnerships for screening and myopia control programs.

• How profitability is generated:
  • High ASPs (average selling prices) for prescription orthokeratology lenses and clinic-installed equipment drive gross margins.
  • Recurring revenue from consumables (care solutions, replacement lenses) and clinic service fees increases customer lifetime value.
  • Optometry technology services and managed optical terminals create stable service income and strengthen distribution partnerships.
  • Scale in manufacturing and vertically integrated supply chain supports operating efficiencies reflected in a >40% operating margin.

Autek China Inc. (300595.SZ): How It Makes Money

• Primary product lines: autorefractors, corneal topographers, orthokeratology fitting systems, and myopia-control management platforms.
• Channels: direct sales to hospitals and eye clinics, distributor networks, school screening programs, and partnerships with optical retailers.
• Recurring revenue: consumables, software subscriptions, maintenance and data services.

• Market role: A significant domestic player in China's eye health equipment segment focused on myopia control and early screening.
• Competition: Faces both domestic rivals and multinational ophthalmic-device companies competing on technology, distribution and price.
• Analyst consensus: Forecast 12% CAGR over the next five years, driven by product innovation, expanding service offerings and broader adoption of myopia-management protocols.
• Geographic expansion: Targeting Southeast Asia with an expected 20% increase in regional sales over three years as clinics adopt similar screening and myopia-control demand rises.
• M&A strategy: Reportedly in talks to acquire a smaller competitor-which could boost market share by ~15% and add complementary technologies (e.g., advanced fittings, software modules).

• R&D-led product upgrades to capture higher ASPs and expand to premium clinical segments.
• Scaling recurring SaaS and consumable sales to improve revenue visibility and margins.
• Channel expansion-school screening contracts and Southeast Asian distributors-to lift unit volumes.
• Selective acquisitions to accelerate technology access and consolidate domestic share.